Aoife Brennan is recorded as CFO at Climb Bio, Inc. (CLYM) since May 24, 2025, Board Member at Climb Bio, Inc. (CLYM) since June 12, 2024, CEO at Climb Bio, Inc. (CLYM) and Board Member at Xilio Therapeutics, Inc. (XLO). The newest filing on record that lists Aoife Brennan as CEO at Climb Bio, Inc. (CLYM) is dated April 24, 2026. The newest filing on record that lists Aoife Brennan as Board Member at Xilio Therapeutics, Inc. (XLO) is dated April 28, 2026. Earlier roles on record: CEO and Board Member at Synlogic, Inc. (SYBX) until March 9, 2024. Climb Bio, Inc. reported in an 8-K filed May 23, 2025 that Aoife Brennan was appointed interim principal financial officer, effective May 24, 2025. Climb Bio, Inc. reported in an 8-K filed June 27, 2024 that Aoife Brennan was appointed Board of Directors. Climb Bio, Inc. reported in an 8-K filed June 27, 2024 that Aoife Brennan was appointed President and Chief Executive Officer. Equibles holds 7 filed executive changes naming Aoife Brennan; each is listed under recent activity with its source filing. The proxy statement of Climb Bio, Inc. reports total compensation of $2,922,223 for Aoife Brennan in fiscal 2025, including a base salary of $669,500. Disclosed compensation is on record for 2 fiscal years. Aoife Brennan has spoken on 10 earnings calls and 2 other investor events across 2 companies, most recently for Climb Bio, Inc. on September 16, 2026. Those appearances were for Synlogic, Inc. (SYBX) and Climb Bio, Inc. (CLYM). Climb Bio, Inc. is classified in the Biotechnology industry within the Healthcare sector. Xilio Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Aoife Brennan spoke on are classified in the Healthcare sector. Other leadership on record at Climb Bio, Inc. includes Aoife Brennan, M.B., Ch.B. (CEO and Board Member), Dr. Stephen Thomas (CEO), Stephen Thomas (CEO and Board Member) and 7 others.
“On the Separation Date, the Board of Directors of the Company appointed Aoife Brennan as the Company’s interim principal financial officer, effective as of May 24, 2025.”
Climb Bio, Inc. Form 8-K, filed May 23, 2025
· Read the filing
“Dr. Aoife Brennan and Dr. Stephen Thomas will also join Eliem's Board of Directors.”
Climb Bio, Inc. Form 8-K, filed June 27, 2024
· Read the filing
Aoife Brennan on recent calls
“Yeah, so for those of you new to the Climb story, Climb was really founded around the thesis that there was a lot of unmet need in B-cell mediated diseases. There were validated targets that hadn't been fully exploited.”
“We have two antibody approaches in renal disease and other autoimmune diseases. Our lead program is our CD19 monoclonal antibody, Budoprutug. Prutug, and that is in development in phase 2 for PMN, in phase 1b for ITP and SLE, and we can go through the cadence of readouts there.”
“I'm happy to share an update today on our recent progress, the financial results for the second quarter of 2022 and upcoming milestones. This is an exciting time for Synlogic and the synthetic biotic platform.”
“I'm happy to share with you today updates on our recent progress, as well as our financial results for the first quarter of 2022. We've had a busy first quarter with significant progress.”
“I'm thrilled to share with you today, updates on our recent progress, as well as our financial results from the fourth-quarter and full-year of 2021. In 2021 the Synlogic team achieved dramatic progress across the portfolio.”
